Launxp Biomedical Co (ROCO:6876) ROCE % : -45.29% (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Launxp Biomedical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Launxp Biomedical Co's annualized ROCE % for the quarter that ended in Jun. 2024 was -45.29%.

Launxp Biomedical Co ROCE % Historical Data

The historical data trend for Launxp Biomedical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Launxp Biomedical Co ROCE % Chart

Launxp Biomedical Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-49.99

-55.03

-92.80

-76.99

Launxp Biomedical Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial			-48.11	-101.72	-98.50	-75.13	-45.29

Launxp Biomedical Co ROCE % Calculation

Launxp Biomedical Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-80.782	/	( ( (32.443 - 7.581)	+	(206.489 - 21.492) )	/ 2 )
	=	-80.782	/	( (24.862	+	184.997)	/ 2 )
	=	-80.782	/	104.9295
	=	-76.99 %

Launxp Biomedical Co's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-75.664	/	( ( (206.489 - 21.492)	+	(161.885 - 12.771) )	/ 2 )
	=	-75.664	/	( ( 184.997	+	149.114 )	/ 2 )
	=	-75.664	/	167.0555
	=	-45.29 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Launxp Biomedical Co (ROCO:6876) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Launxp Biomedical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Launxp Biomedical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Launxp Biomedical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Launxp Biomedical Co Ltd (ROCO:6876) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

10F, No. 51, Section 2, Gongyi Road, Nantun District, Taichung, TWN, 408

Website

https://www.launxp.com

Launxp Biomedical Co Ltd is a company that researches, designs and develops Cancer drug rapid screening platform and Early development evaluation and technology licensing of generic drugs for cancer treatment. The company mainly focuses on the screening of development drugs, formulation of development strategies, project management, planning and execution of regulations and clinical trials, etc.

Launxp Biomedical Co Headlines

No Headlines